EX-99 2 exhibit_a.htm EXHIBIT A
 
EXHIBIT A
 
JOINT FILING AGREEMENT
 
In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G/A (including any and all amendments thereto) with respect to the Common Stock, par value $0.01 per share, of Eloxx Pharmaceuticals, Inc. and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filing. In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of April 29, 2019.
 
 
Catalyst CEL Fund L.P.
   
Dated: April 29, 2019
By:
/s/ Edouard Cukierman
 
 
Name:
 
Edouard Cukierman
 
 
Title:
 
Authorized Signatory
         
Dated: April 29, 2019
By:
/s/ Yair Shamir
  
 
 
Name:
 
Yair Shamir
 
 
Title:
 
Authorized Signatory
     
 
CEL CATALYST China Israel Fund L.P.
   
Dated: April 29, 2019
By:
/s/ Edouard Cukierman
 
 
Name:
 
Edouard Cukierman
 
 
Title:
 
Authorized Signatory
         
Dated: April 29, 2019
By:
/s/ Yair Shamir
  
 
 
Name:
 
Yair Shamir
 
 
Title:
 
Authorized Signatory
   
 
CEL Catalyst  China Israel General Partner Limited
   
Dated: April 29, 2019
By:
/s/ Edouard Cukierman
 
 
Name:
 
Edouard Cukierman
 
 
Title:
 
Authorized Signatory
         
Dated: April 29, 2019
By:
/s/ Yair Shamir
  
   
Name:
 
Yair Shamir
   
Title:
 
Authorized Signatory
 
Catalyst CEL Management Ltd.
   
Dated: April 29, 2019
By:
/s/ Edouard Cukierman
 
 
Name:
 
Edouard Cukierman
 
 
Title:
 
Authorized Signatory
         
Dated: April 29, 2019
By:
/s/ Yair Shamir
  
 
 
Name:
 
Yair Shamir
 
 
Title:
 
Authorized Signatory